A Stable Isopterin Mimic of a Potent Bacterial Stimulant of T Cells
Chemistry – A European Journal · 03.11.2026 · 32 (41)
DOI: 10.1002/chem.71494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, online erschienen am 14.08.2026. Verfasst von Jeffrey Y W Mak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Chemistry and Drug Discovery and ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscien…. Hauptthemen laut MEDLINE: Mucosal-Associated Invariant T Cells, Uracil, Ribitol, T-Lymphocytes. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US National Institutes of Health, National Health and Medical Research Council of Australia, Australian Research Council.
Abstract (Originalsprache)
Mucosal‐associated invariant T cells (MAIT cells) are innate‐like immune cells (T lymphocytes) that protect against bacterial infections. They are potently activated by the microbial metabolite 5‐(2‐oxopropylideneamino)‐ d ‐ribitylaminouracil (5‐OP‐RU), which bonds covalently to an amine of a specific lysine residue of the antigen‐presenting protein MR1 to form an imine (Schiff base). However, 5‐OP‐RU undergoes rapid degradative intramolecular cyclisation in water, and more robust analogues are needed for therapeutic applications. Here, inspired by the structural similarities between 5‐OP‐RU and 6‐formylpterin, a water‐stable covalent MR1 ligand that does not activate MAIT cells, we describe the design and synthesis of a novel isopterin analogue of this microbial natural product, and show that it is both water‐stable and activates reporter cells expressing the MAIT T cell receptor. Further, we present a protein‐bound crystal structure and molecular dynamics simulations of this stable analogue to show that it mimics the MR1‐bound conformation of 5‐OP‐RU. This study demonstrates the potential of this bicyclic scaffold for stabilising 5‐OP‐RU mimetics, advances our understanding of the molecular requirements for MR1 binding and MAIT cell activation, and informs the design and synthesis of future MAIT cell antigens as potential immunotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Chemistry and Drug Discovery and ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
- Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute For Infection and Immunity, Melbourne, Victoria, Australia.
ORCID-Profile: Jeffrey Y W Mak, Wael Awad, Xin Yi Lim, Damica D Laurie, Ryan J D Rivero, James McCluskey, Alexandra J Corbett, David P Fairlie
Förderung
- US National Institutes of Health
- National Health and Medical Research Council of Australia
- Australian Research Council
Zitieren
APA
Mak, J. Y. W., Hoang, H. N., Awad, W., Lim, X. Y., Laurie, D. D., Rivero, R. J. D., McCluskey, J., Corbett, A. J., Rossjohn, J., & Fairlie, D. P. (2026). A Stable Isopterin Mimic of a Potent Bacterial Stimulant of T Cells. Chemistry – A European Journal, 32(41). https://doi.org/10.1002/chem.71494
Vancouver
Mak JYW, Hoang HN, Awad W, Lim XY, Laurie DD, Rivero RJD, et al. A Stable Isopterin Mimic of a Potent Bacterial Stimulant of T Cells. Chemistry – A European Journal. 2026;32(41). doi:10.1002/chem.71494
BibTeX
@article{Mak2026,
author = {Mak, Jeffrey Y W and Hoang, Huy N and Awad, Wael and Lim, Xin Yi and Laurie, Damica D and Rivero, Ryan J D and McCluskey, James and Corbett, Alexandra J and Rossjohn, Jamie and Fairlie, David P},
title = {A Stable Isopterin Mimic of a Potent Bacterial Stimulant of T Cells},
journal = {Chemistry – A European Journal},
year = {2026},
volume = {32},
number = {41},
doi = {10.1002/chem.71494}
}
EUVIMED